This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
ZTS Q2 Earnings & Revenues Beat Estimates, '25 Outlook Raised
by Zacks Equity Research
Zoetis posts better-than-expected Q2 results with rising sales of pet medicines, boosting its 2025 outlook.
TGTX Down as Q2 Earnings Miss Mark, Briumvi Sales Drive Top Line
by Zacks Equity Research
TG Therapeutics slides 18% as second-quarter earnings fall short despite a 92% revenue jump fueled by surging Briumvi sales.
FOLD Q2 Earnings Miss Mark, Revenues Beat on Higher Product Sales
by Zacks Equity Research
Amicus misses second-quarter earnings estimates but beats the same for revenues, driven by strong sales of Galafold and Pombiliti + Opfolda.
Bausch Health Stock Falls on Q2 Earnings Miss, Revenues Beat
by Zacks Equity Research
BHC stock falls 6.3% as Q2 earnings miss estimates despite stronger sales and growth in key segments like Salix and Solta Medical.
Amarin's Q2 Earnings & Revenues Trump Estimates, Stock Rises
by Zacks Equity Research
AMRN beats second-quarter estimates for earnings. Revenues rise year over year on strong licensing gains.
UTHR Q2 Earnings Miss Estimates, Higher Tyvaso Sales Aid Revenues Y/Y
by Zacks Equity Research
United Therapeutics' second-quarter earnings miss estimates, while revenues rise 12% on strong Tyvaso and other product sales.
Alkermes Q2 Earnings Beat Estimates, Proprietary Drugs Aid Sales
by Zacks Equity Research
ALKS beats second-quarter estimates as proprietary product sales rise 14% y/y, offsetting weaker manufacturing and royalty revenues.
JNJ Seeks FDA Approval for Oral Psoriasis Drug Icotrokinra
by Zacks Equity Research
Johnson & Johnson eyes FDA nod to icotrokinra after phase III studies show strong skin clearance and safety in plaque psoriasis.
ALKS Down Despite Positive Top-Line Data From Narcolepsy Study
by Zacks Equity Research
Alkermes falls 8.8% despite alixorexton hitting key goals in a narcolepsy type 1 study, as cataplexy data stirs investor concerns.
RCKT Stock Up on FDA's RMAT Tag to Gene Therapy for Heart Failure
by Zacks Equity Research
Rocket Pharmaceuticals jumps 16.8% as FDA grants RMAT status to RP-A601 on positive phase I heart disease data.
FDA Advisory Panel Votes Against Approval of GSK's Blenrep Combo
by Zacks Equity Research
GSK stock falls as an FDA panel votes against its Blenrep combo, casting doubt on U.S. approval hopes.
Mirum Gains 35% in 3 Months: How Should You Play the Stock?
by Zacks Equity Research
MIRM jumps 35% in 3 months, driven by soaring Livmarli sales and rising demand for its bile acid products.
Sanofi's Gene Therapy for Eye Disease Gets FDA's Fast Track Tag
by Zacks Equity Research
SNY's SAR446597, a one-time intravitreal gene therapy, secures FDA fast track tag for geographic atrophy due to age-related macular degeneration.
Corcept Seeks FDA Approval for Relacorilant in Ovarian Cancer
by Zacks Equity Research
CORT's relacorilant combo targets platinum-resistant ovarian cancer in new NDA, backed by positive ROSELLA study data.
FDA Rejects CAPR's Cell Therapy BLA for Genetic Disorder, Stock Tanks
by Zacks Equity Research
Capricor slumps 33% as the FDA rejects its BLA for DMD drug, deramiocel, citing lack of effectiveness data and CMC issues.
Wall Street Analysts Believe Arvinas (ARVN) Could Rally 89.85%: Here's is How to Trade
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 89.9% in Arvinas (ARVN). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Does Arvinas (ARVN) Have the Potential to Rally 94.93% as Wall Street Analysts Expect?
by Zacks Equity Research
The consensus price target hints at a 94.9% upside potential for Arvinas (ARVN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Arvinas, Inc. (ARVN) Q1 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Arvinas (ARVN) delivered earnings and revenue surprises of 232.56% and 332.53%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Apellis Pharmaceuticals, Inc. (APLS) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
by Zacks Equity Research
Apellis Pharmaceuticals (APLS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
After Plunging -25.42% in 4 Weeks, Here's Why the Trend Might Reverse for Arvinas (ARVN)
by Zacks Equity Research
The heavy selling pressure might have exhausted for Arvinas (ARVN) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
OPTN Stock Soars 53% on Inking $330M Deal to be Acquired by Paratek
by Zacks Equity Research
OptiNose stock surges 53% as it is set to be acquired by Paratek for $330 million, adding chronic rhinosinusitis drug, Xhance, to the latter's portfolio.
Mirum's Heavy Dependence on Livmarli for Revenues Remains a Woe
by Zacks Equity Research
MIRM's high reliance on lead drug, Livmarli for revenues remains a worry. Failure to generate sufficient revenues from Livmarli sales is likely to hurt the stock.
PSTV Stock Surges as FDA Accepts Proprietary Name for Lead Drug
by Zacks Equity Research
The FDA conditionally accepts Plus Therapeutics' new proprietary name, Reyobiq, for its lead therapeutic candidate. Stock shoots up.
ESPR to Study Bempedoic Acid in Pediatric Familial Hypercholesterolemia
by Zacks Equity Research
Esperion plans to begin two phase III studies on bempedoic acid alone and in combination with ezetimibe in pediatric patients with familial hypercholesterolemia.
IMVT Unlikely to Pursue Batoclimab for MG & CIDP Despite Success
by Zacks Equity Research
Immunovant's batoclimab shows strong efficacy in MG & CIDP, but shifts focus to the lead drug IMVT-1402 for these indications to induce deeper, lasting relief.